NOVO-DIPIRADOL TAB 50MG TABLET

Land: Kanada

Sprache: Englisch

Quelle: Health Canada

Wirkstoff:

DIPYRIDAMOLE

Verfügbar ab:

NOVOPHARM LIMITED

ATC-Code:

B01AC07

INN (Internationale Bezeichnung):

DIPYRIDAMOLE

Dosierung:

50MG

Darreichungsform:

TABLET

Zusammensetzung:

DIPYRIDAMOLE 50MG

Verabreichungsweg:

ORAL

Einheiten im Paket:

100/1000

Verschreibungstyp:

Prescription

Therapiebereich:

MISCELLANEOUS VASODILATATING AGENTS

Produktbesonderheiten:

Active ingredient group (AIG) number: 0106621002; AHFS:

Berechtigungsstatus:

CANCELLED POST MARKET

Berechtigungsdatum:

2005-08-10

Fachinformation

PRODUCT MONOGRAPH
Pr
NOVO-DIPIRADOL (dipyridamole) 25, 50, 75, 100 mg Tablets
Pr
DIPYRIDAMOLE FOR INJECTION (dipyridamole) 5 mg/mL, USP
Coronary Vasodilator
Inhibitor of Platelet Adhesion and Aggregation
Novopharm Limited
Date of Preparation:
30 Novopharm Court
October 26, 2006
Toronto, Ontario
M1B 2K9
Control No. 107491
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION......................................................... 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL
USE.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
3
WARNINGS AND
PRECAUTIONS.........................................................................................
4
ADVERSE
REACTIONS...........................................................................................................
5
DRUG INTERACTIONS
...........................................................................................................
8
DOSAGE AND
ADMINISTRATION.......................................................................................
9
OVERDOSAGE
.........................................................................................................................
9
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 10
STORAGE AND
STABILITY.................................................................................................
11
SPECIAL HANDLING INSTRUCTIONS
..............................................................................
11
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................... 11
PART II: SCIENTIFIC INFORMATION
...............................................................................
13
PHARMACEUTICAL
INFORMATION.........................................................